Find Funding Opportunities

This Announcement solicits applications for the early-stage development of therapeutics to mitigate the adverse health effects resulting from toxic chemical exposure. Chemical threats are toxic compounds that could be used in a terrorist attack or accidentally released from industrial production, storage or shipping. They include specific chemical warfare agents, toxic industrial chemicals, pesticides, and pharmaceutical-based agents. The overall scope of this solicitation includes validation of therapeutic targets and preclinical characterization of lead compounds. The UG3 phase of this announcement supports target validation and characterization of initial lead compound(s); UH3 phase activities include candidate optimization and in vivo demonstration of activity and efficacy in relevant post-exposure models. At the conclusion of the overall UG3/UH3 funding period, projects are expected to deliver at least one well-characterized therapeutic candidate.

Removing PEDP as it is not a responsive criteria.

The Office of Research on Womens Health (ORWH) announces the availability of administrative supplements to support research to address health disparities among women in the United States who are underrepresented, underserved, and underreported (U3) in biomedical research.

Technical Assistance Webinars for RFA-NS-25-024 Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)

The purpose of this time-sensitive Request for Information (RFI) is to seek input from scientists, clinicians, patients, families, caregivers, advocates, and the broader dementia community on the most important needs and promising opportunities for Alzheimer's disease-related dementias (ADRD) research. The information submitted in response to this RFI will be used by committees of scientists, clinicians, and other members of the public to revise and update the ADRD 2019 research recommendations.

The National Institute for Neurological Disorders and Stroke (NINDS) is interested in applications that fall within the NINDS mission space: https://www.ninds.nih.gov/about-ninds/what-we-do/ninds-mission. Applicants are strongly encouraged to confirm NINDS mission fit with the NINDS Small Business Program prior to submission.

Changing first receipt date.

This NOFO solicits applications for next generation sensor and bioelectronic device development that will synchronize with brain recordings. The sensor and neural recording data will be used to generate new computational models of behavior in human and animal models. There has been a lack of quantitative approaches and models to understand the complexity of human and animal behavior in naturalistic settings. This NOFO focuses on the development of next generation sensors to acquire data and synchronize it with simultaneous brain recordings to build computational models.

Please join us for a preapplication technical assistance webinar to discuss RFA-NS-24-041 NIH HEAL Initiative: Coordinated Approaches to Pain Care in Health Care Systems (UG3/UH3 - Clinical Trial Optional). This RFA will support applications that propose implementation science methodology to embed existing evidence-based coordinated pain care models into a variety of public and private health care systems (HCS) where this type of care does not exist. The purpose of this webinar is to provide potential grant applicants with an overview of the RFA and address questions from the scientific community. The webinar will feature highlights of application considerations from program staff at National Institute of Neurological Disorders and Stroke (NINDS) and the National Center for Complementary and Integrative Health (NCCIH). It will also include a presentation on review requirements from NCCIHs Office of Scientific Review.

This Notice of Special Interest (NOSI) is to solicit applications to support a series of annual scientific meetings for the Chemical Countermeasures Research Program (CCRP).